

FORM PTO-1595  
1-31-92  
(modified)

RECORDATION FORM COVER SHEET  
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313-1450, Patent and Trademark Assignment System, at (703) 306-5995, on

Date March 30, 2004  
Signature Renee McArthur

To the Commissioner of Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):  
**AVENTIS PHARMACEUTICALS INC.**

2. Name and address of receiving party(ies):  
Name: **AVENTIS PHARMA DEUTSCHLAND GMBH**  
Internal  
Address:  
Street Address: **Industriepark Hoechst, Gebaude K 801**  
City: **Frankfurt am Main** Country **GERMANY** ZIP: **65926**

Additional name(s) of conveying party(ies) attached?  YES  NO

3. Nature of Conveyance:  
 Assignment  Merger  
 Security Agreement  Change of Name  
 Other

Additional name(s) and address(es) attached?  YES  NO

Execution Date: **October 31, 2003**

4. Application number(s) or patent number(s):  
If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s): **10/404,678** | B. Patent No.(s):  
Additional numbers attached?  YES  NO

5. Name and address of party to whom correspondence concerning document should be mailed:  
Name: **Raymond S. Parker, III, Ph.D., Reg. No. 34,893**  
Internal Address: **Aventis Pharmaceuticals Inc.**  
Street Address: **Route 202-206 / P.O. Box 6800**  
City: **Bridgewater** State: **NJ** ZIP: **08807-0800**  
**\*\* FAX NUMBER: (908) 231-2626 \*\***  
Our Reference No.: **DEAV2000/S007 US CNT**

6. Total number of applications and patents involved: **1**  
7. Total (37 CFR 3.41): ..... **\$40.00**  
 Enclosed  
 Authorized to be charged to deposit account

8. Deposit account number: **18-1982**

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Raymond S. Parker, III, Ph.D., Reg. No. 34,893  
Name of Person Signing

  
Signature

Date: March 30, 2004  
Total number of pages comprising cover sheet: **3**

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion  
Mail documents to be recorded with required cover sheet information to:  
Mail Stop Assignments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office Information Systems, PK2-1000C, Alexandria, VA 22313, and to the Office of Management and Budget, Paperwork Reduction Project (0561-0011), Alexandria, VA 22313.

GH \$40.00 181982 10404678

Aventis File No. DEAV2000/S007

**ASSIGNMENT AND AGREEMENT**

For value received and intending to be legally bound, we, **AVENTIS PHARMACEUTICALS INC.**, of 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807-2854, United States of America, (Assignor), sell, assign and transfer to **AVENTIS PHARMA DEUTSCHLAND GMBH**, Industriepark Hoechst, Gebaude K. 801, 65926 Frankfurt am Main, Germany, (Assignee), and its successors, assigns and legal representatives, the entire right, title and interest in and to the invention and any improvements thereon for all countries of the world, relating in and to the priority applications listed below and entitled

**NOVEL CRYSTALLINE FORMS OF A FACTOR X<sub>a</sub> INHIBITORS****1<sup>ST</sup> PRIORITY APPLICATION:**

**US Provisional Application No. 60/238,316 filed October 5, 2000**  
for which ownership rights are the subject of an assignment from the Inventors to Aventis Pharmaceuticals Inc. which was recorded in the USPTO on September 11, 2003 at Reel/Frame: 013965/0077.

**2<sup>ND</sup> PRIORITY APPLICATION:**

**GB Application No. 0108903.6 filed April 10, 2001**

**INTERNATIONAL APPLICATION**

**PCT Application No. US01/31087 filed October 4, 2001**

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said priority applications, and under any and all Letters Patent which may be granted therefore, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of the above applications, and any and all patents which may issue thereon, and any reissues, pipelines and extensions, and governmental exclusivity rights of the same.

We authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

Aventis File No. DEAV2000/S007

We agree that, when requested, we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

We covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have full right to convey the same as herein expressed.

Signed at Bridgewater NJ, USA on this 31<sup>st</sup> day of October, 2003.  
(City, State and Nation)

AVENTIS PHARMACEUTICALS INC.

By:   
\_\_\_\_\_  
Ross J. Oehler  
Assistant Secretary